girentuximab Report issue

Biologics mAb Experimental
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Girentuximab is a chimeric IgG1 monoclonal antibody to carbonic anhydrase IX (CAIX). CAIX is expressed on the surface of most renal cancer cells and is hypothesized to be on the surface of other tumor cells. It is investigational agent in clinical trials for renal cell carcinoma. Its development was suspended as a "naked" or unconjugated antibody during phase III trials due to efficacy.   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: No
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Alternative names

111indium-cg250 | 124i cg250 | 124i-cg250 | 124i girentuximab | ca9-scan cg250 | cg250 | cg-250 | cg250 (111in) | cg250 mab | g250 | g-250 | g250 mab | g250 monoclonal antibody | g250 peptide | girentuximab | indium | iodine (124i) girentuximab | lu177-dota-girentuximab | monoclonal antibody g250 | rencarex | wx-g250 | zr89 girentuximab

Organizations (12)

Research & Development (12)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (3)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (3)


 

Carcinoma, Renal Cell (Phase 3)

Carcinoma, Transitional Cell (Phase 1)

Kidney Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 14
  • # of Trial Organizations: 12

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue